// App-Quantinova.ai

e18558 : CXCR4 expression and circulating tumor cell (CTC) counts evaluated as prognostic markers in extensive disease small cell lung cancer (ED-SCLC) patients (pts).

Researchers

Presenter

  • John R Stille

Principal Investigators

  • Amy Flynt

  • Victoria L Peek

  • Stephanie Roberson

  • Renouard Sanders

  • Suzane L. Um

  • Sameera R. Wijayawardana

  • Mark Carle Connelly

  • Kurt Baeten

  • Oday Hamid

  • Carrie Morano

  • Eyas Raddad

  • Madeline Ivette Repollet

  • S. Betty Yan

  • Steven Gross

  • Jan Keij

Medical Centers

  • Veridex LLC, Huntingdon Valley, PA

  • Statistics, Eli Lilly and Company, Indianapolis, INMedical Affairs, Janssen Diagnostics, Beerse, BelgiumOncology Medical, Eli Lilly and Company, Indianapolis, IN

  • PharPoint Research Inc., Durham, NC

  • Eli Lilly and Company, Indianapolis, IN

  • Oncology Discovery Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN.

  • CRS Lab Operations, Janssen Diagnostics, Huntingdon Valley, PA

  • Oncology Discovery Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN.

  • Research and Development, Janssen Diagnostics, Huntingdon Valley, PA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Small cell lung cancer

Biomarkers

  • Circulating tumor cells

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved